Background: To evaluate protection, pharmacokinetics, and optimum tolerated dosage of roniciclib in sufferers with advanced malignancies, with dosage expansion to judge clinical benefit on the recommended stage II dosage (RP2D). statusa, (%)????????01 (10.0)24 (60.0)3 (42.9)9 (27.3)9 (36.0)2 (33.3)47 (42.3)?18 (80.0)12 (30.0)3 (42.9)23 (69.7)14 (56.0)4 (66.7)56 (50.5)?2CC1 (14.3)CCC1 (0.9)Preceding systemic therapy (neoadjuvant, adjuvant, palliative, and/or curative),… Continue reading Background: To evaluate protection, pharmacokinetics, and optimum tolerated dosage of roniciclib